PredicineHEMEā¢
Use
PredicineHEMEā¢ is a 259-gene NGS assay designed for the detection and characterization of hematologic malignancies. It helps guide decisions for immunotherapy, targeted therapy, and relevant clinical trials for blood cancers. The test further measures critical biomarkers in B-cell malignancies, including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL). It is optimized for treatment selection, disease monitoring, and drug resistance detection.
Special Instructions
Not provided.
Limitations
The assay may have limitations in detection sensitivity beyond the specified threshold (ā„0.05% for variant detection) and might not identify all driver mutations or have limited utility for atypical or complex karyotype presentations not covered by the gene list.
Methodology
NGS (Targeted)
Biomarkers
No genes
Gene
Result Turnaround Time
6 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
2-5 mL
Minimum Volume
Not provided